Human Advanced Glycosylation End Product Specific Receptor (AGER) Protein

Este producto es parte de AGE - Advanced Glycation End Product (Receptor)
Product Graph
247€ (10 µg)

Por favor contáctenos para obtener información detallada sobre el precio y disponibilidad.

935106861
info@markelab.com
name
Human Advanced Glycosylation End Product Specific Receptor (AGER) Protein
category
Proteins and Peptides
provider
Abbexa
reference
abx065184
tested applications
WB, SDS-PAGE

Description

Recombinant Advanced Glycosylation End Product Specific Receptor (AGER) is a recombinant Human protein produced in a Prokaryotic expression system (E. coli).

Documents del producto

Instrucciones
Data sheet
Descargar

Product specifications

Category
Proteins and Peptides
Immunogen Target
Advanced Glycosylation End Product Specific Receptor (AGER)
Host
E. coli
Origin
Human
Conjugation
Unconjugated
Observed MW
Molecular Weight: Calculated MW: 26.1 kDa
Concentration: Prior to lyophilization: 200 µg/ml
Sequence Fragment: Ile91-Asp274 plus NQARRGQLQALWEDQGWEL
Tag: N-terminal His tag
Expression
Recombinant
Purity
> 97%
Size 1
10 µg
Size 2
50 µg
Size 3
100 µg
Size 4
200 µg
Size 5
500 µg
Form
Lyophilized To keep the original salt concentration, we recommend reconstituting to the original concentration prior to lyophilization (see Concentration) in ddH2O. If a lower concentration is required, dilute in PBS, pH 7.4. If a higher concentration is required, the product can be reconstituted directly in PBS, pH 7.4, though please note that this will change the overall salt concentration. The stock concentration should be between 0.1-1.0 mg/ml. Do not vortex.
Tested Applications
WB, SDS-PAGE
Buffer
Prior to lyophilization: PBS, pH 7.4, containing 0.01% Sarcosyl, 1 mM DTT, 5% Trehalose and Proclin-300.
Availability
Shipped within 5-7 working days.
Storage
Store at 2-8 °C for up to one month. Store at -80 °C for up to one year. Avoid repeated freeze/thaw cycles.
Dry Ice
No
UniProt ID
Q15109
Alias
RAGE,SCARJ1,sRAGE
Background
Protein AGER
Status
RUO
Note
This product is for research use only.   Not for human consumption, cosmetic, therapeutic or diagnostic use.

Descripción

AGER, also known as RAGE (Receptor for Advanced Glycation End Products), is a transmembrane receptor belonging to the immunoglobulin superfamily that binds to AGEs and other ligands such as S100 proteins, HMGB1, and amyloid-β. AGER is widely expressed, particularly in the endothelium, lungs, brain, and immune cells, and plays a critical role in inflammatory and oxidative stress signaling. Binding of AGEs to AGER activates downstream pathways, including NF-κB, MAPK, and JAK/STAT, leading to the production of pro-inflammatory cytokines and reactive oxygen species. Overexpression or chronic activation of AGER is associated with diseases such as diabetes complications, atherosclerosis, Alzheimer’s disease, and cancer, where it exacerbates inflammation and tissue damage. AGER is a promising therapeutic target for reducing AGE-mediated pathologies and modulating immune and metabolic dysfunction.

Related Products

EM0526

Mouse AGER(Advanced Glycosylation End Product Specific Receptor) ELISA Kit

Ver Producto
FNab00209

anti- AGER antibody

Mediates interactions of advanced glycosylation end products(AGE). These are nonenzymatically glycosylated proteins which accumulate in vascular tissue in aging and at an accelerated rate in diabetes. Acts as a mediator of both acute and chronic vascular inflammation in conditions such as atherosclerosis and in particular as a complication of diabetes. AGE/RAGE signaling plays an important role in regulating the production/expression of TNF-alpha, oxidative stress, and endothelial dysfunction in type 2 diabetes. Interaction with S100A12 on endothelium, mononuclear phagocytes, and lymphocytes triggers cellular activation, with generation of key proinflammatory mediators. Interaction with S100B after myocardial infarction may play a role in myocyte apoptosis by activating ERK1/2 and p53/TP53 signaling(By similarity). Receptor for amyloid beta peptide. Contributes to the translocation of amyloid-beta peptide(ABPP) across the cell membrane from the extracellular to the intracellular space in cortical neurons. ABPP-initiated RAGE signaling, especially stimulation of p38 mitogen-activated protein kinase(MAPK), has the capacity to drive a transport system delivering ABPP as a complex with RAGE to the intraneuronal space. Can also bind oligonucleotides.

Ver Producto
FNab09951

anti- AGER antibody

Mediates interactions of advanced glycosylation end products(AGE). These are nonenzymatically glycosylated proteins which accumulate in vascular tissue in aging and at an accelerated rate in diabetes. Acts as a mediator of both acute and chronic vascular inflammation in conditions such as atherosclerosis and in particular as a complication of diabetes. AGE/RAGE signaling plays an important role in regulating the production/expression of TNF-alpha, oxidative stress, and endothelial dysfunction in type 2 diabetes. Interaction with S100A12 on endothelium, mononuclear phagocytes, and lymphocytes triggers cellular activation, with generation of key proinflammatory mediators. Interaction with S100B after myocardial infarction may play a role in myocyte apoptosis by activating ERK1/2 and p53/TP53 signaling(By similarity). Receptor for amyloid beta peptide. Contributes to the translocation of amyloid-beta peptide(ABPP) across the cell membrane from the extracellular to the intracellular space in cortical neurons. ABPP-initiated RAGE signaling, especially stimulation of p38 mitogen-activated protein kinase(MAPK), has the capacity to drive a transport system delivering ABPP as a complex with RAGE to the intraneuronal space. Can also bind oligonucleotides.

Ver Producto